IN Brief:
- FSSAI has ordered PIE Foods to stop selling two products containing monk fruit extract.
- Licensing endorsements, mandatory declarations, and advertising claims were among the deficiencies identified.
- PIE Foods must also secure the required approval covering monk fruit extract as a non-specified food ingredient.
India’s Food Safety and Standards Authority has ordered PIE Foods to stop selling two monk fruit sweetener products after an inspection identified deficiencies covering licensing, labelling, e-commerce activity, advertising claims, and ingredient approval.
The prohibition applies to Monk Fruit Extract Sweetener and Monk Fruit Sweetener Drops containing monk fruit extract. FSSAI has directed the business to obtain the appropriate central licence endorsements and secure the required approval covering the non-specified food ingredient before the affected products can return to sale.
The regulator identified several separate compliance failures. Some cartons carried the wording “Marketed by PIE FOODS” without a valid relabeller Kind of Business endorsement in the company’s FSSAI licence, while the company was also operating an e-commerce website without the required e-commerce endorsement.
FSSAI also found that product labels lacked mandatory declarations and carried claims including “100% Monk Fruit Extract” and “Natural Ingredients”, while the e-commerce website displayed the claim “Doctor Recommended”. The authority said the issues breached India’s labelling and display requirements and its advertising and claims rules.
The action demonstrates why food-business licensing and ingredient approval have to be treated as separate controls. A company may hold a central food licence while still lacking the endorsements required for a particular business activity or the approval needed for a specific formulation.
That distinction matters particularly for novel or non-standardised ingredients. FSSAI operates a dedicated approval route for foods and food ingredients that are not covered by existing standards, requiring applicants to submit supporting material for scientific assessment before commercial use is authorised.
Monk fruit is used in several markets as the source of intensely sweet compounds, but regulatory status depends on the jurisdiction and on the exact form and specification of the ingredient. A product described broadly as monk fruit can involve different extracts, concentrations, carriers, or processing routes, and approval in one country does not automatically establish compliance in another.
For manufacturers, the immediate consequence is a supplier-qualification problem rather than simply a marketing dispute. Technical teams evaluating a sweetener need evidence covering composition, specification, safety, regulatory status, labelling implications, and permitted claims as well as cost and sensory performance.
A failure at that stage can spread through production quickly. If an ingredient is used across several finished products, a regulatory restriction can affect raw-material inventory, printed packaging, production schedules, customer orders, and finished stock simultaneously. Where the ingredient itself lacks the required approval, changing a label does not resolve the underlying issue.
The case also shows how licence scope can change as a business model develops. A company that begins with manufacturing or distribution may later add relabelling, direct-to-consumer sales, or e-commerce operations. Those commercial changes can create additional regulatory requirements even when the physical product remains unchanged.
Claims create another control point. Phrases developed for packaging or digital marketing ultimately become part of the regulated product proposition, so quality and regulatory teams need oversight of artwork, websites, marketplace listings, and advertising. A claim copied from one sales channel to another can create a compliance issue if its evidence or permitted wording has not been checked.
That linkage is particularly important for ingredients positioned around sugar reduction or perceived naturalness. Marketing teams may want to emphasise origin, purity, health, or professional endorsement, while food law may require those statements to meet specific definitions and evidence thresholds. Manufacturing businesses need a process that prevents commercial copy from outrunning the regulatory dossier.
FSSAI’s direction is for immediate cessation of sales rather than a simple request to amend packaging. The company has been told to correct the relevant licence endorsements and secure the necessary approval for monk fruit extract as a non-specified ingredient. No independently verified evidence was available during drafting that those requirements had already been completed.
For ingredient buyers, that makes regulatory documentation part of continuity planning. Procurement teams may qualify several technically similar sweeteners, but each supplier’s approval status, manufacturing specification, and permitted claims can differ. A low-cost or high-performing ingredient is of limited value if its regulatory basis cannot withstand inspection.
The enforcement action therefore reaches beyond two individual products. As manufacturers adopt new sweetening systems, plant-derived extracts, and other novel ingredients, the qualification process has to connect formulation, procurement, regulatory affairs, packaging, and digital commerce before products enter routine production. FSSAI’s order shows what happens when those controls are treated as separate administrative tasks rather than one production-release system.
